IRIS Accounts Production v23.2.0.158 02325397 Board of Directors 1.7.22 30.6.23 30.6.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh023253972022-06-30023253972023-06-30023253972022-07-012023-06-30023253972021-06-30023253972021-07-012022-06-30023253972022-06-3002325397ns10:Originalns15:EnglandWales2022-07-012023-06-3002325397ns14:PoundSterlingns10:Original2022-07-012023-06-3002325397ns10:Originalns10:Director12022-07-012023-06-3002325397ns10:Original2022-07-012023-06-3002325397ns10:Original2023-06-3002325397ns10:Originalns10:PrivateLimitedCompanyLtd2022-07-012023-06-3002325397ns10:Originalns10:SmallEntities2022-07-012023-06-3002325397ns10:Originalns10:AuditExempt-NoAccountantsReport2022-07-012023-06-3002325397ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3002325397ns10:SmallCompaniesRegimeForAccountsns10:Original2022-07-012023-06-3002325397ns10:Originalns10:FullAccounts2022-07-012023-06-3002325397ns10:Originalns10:Director22022-07-012023-06-3002325397ns10:Originalns10:RegisteredOffice2022-07-012023-06-3002325397ns10:Original2022-06-3002325397ns5:ShareCapitalns10:Original2023-06-3002325397ns5:ShareCapitalns10:Original2022-06-3002325397ns10:Originalns5:RevaluationReserve2023-06-3002325397ns10:Originalns5:RevaluationReserve2022-06-3002325397ns10:Originalns5:CapitalRedemptionReserve2023-06-3002325397ns10:Originalns5:CapitalRedemptionReserve2022-06-3002325397ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-06-3002325397ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-06-3002325397ns10:Original2021-07-012022-06-3002325397ns10:Originalns5:CostValuation2022-06-3002325397ns10:Originalns5:RevaluationsIncreaseDecreaseInInvestments2023-06-3002325397ns10:Originalns5:CostValuation2023-06-3002325397ns10:Originalns5:CurrentFinancialInstruments2023-06-3002325397ns10:Originalns5:CurrentFinancialInstruments2022-06-3002325397ns10:Originalns5:RevaluationReserve2022-06-30
REGISTERED NUMBER: 02325397 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2023

for

Pharm - Tex Limited

Pharm - Tex Limited (Registered number: 02325397)






Contents of the Financial Statements
for the Year Ended 30 June 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Pharm - Tex Limited

Company Information
for the Year Ended 30 June 2023







DIRECTORS: Nalin Shah
Mrs Nita Shah





REGISTERED OFFICE: 173 Cleveland Street
London
W1T 6QR





REGISTERED NUMBER: 02325397 (England and Wales)





ACCOUNTANTS: Shah Dodhia & Co
173 Cleveland Street
London
W1T 6QR

Pharm - Tex Limited (Registered number: 02325397)

Balance Sheet
30 June 2023

2023 2022
Notes £ £ £ £
FIXED ASSETS
Investments 5 3,412,378 3,203,167

CURRENT ASSETS
Debtors 6 177,991 196,741
Cash at bank 2,240 2,240
180,231 198,981
NET CURRENT ASSETS 180,231 198,981
TOTAL ASSETS LESS CURRENT
LIABILITIES

3,592,609

3,402,148

CAPITAL AND RESERVES
Called up share capital 12,500 12,500
Revaluation reserve 7 3,362,378 3,153,167
Capital redemption reserve 37,500 37,500
Retained earnings 180,231 198,981
3,592,609 3,402,148

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 November 2023 and were signed on its behalf by:





Nalin Shah - Director


Pharm - Tex Limited (Registered number: 02325397)

Notes to the Financial Statements
for the Year Ended 30 June 2023

1. STATUTORY INFORMATION

Pharm - Tex Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities..

The financial statements are prepared in sterling, which is the functional currency of the entity.

Investments in subsidiaries
Investments in subsidiary company is stated at the net asset values of the subsidiary company, which is considered to be their fair values, unless the net asset value is negative, in which case the investment's carrying value is considered to be nil. Differences between the net asset value and historical cost are recognised in other comprehensive income (OCI) in accordance with FRS 102.17.15.E-F, with net revaluation gains recognised in OCI and net revaluation losses in profit and loss to the extent that these are not reversals of previous revaluation gain.

Consolidation
In the opinion of the directors, the company and its subsidiary undertakings comprise a small group. The company has therefore taken advantage of the exemption provided by Section 398 of the Companies Act 2006 not to prepare group accounts.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£
COST OR VALUATION
At 1 July 2022 3,203,167
Revaluations 209,211
At 30 June 2023 3,412,378
NET BOOK VALUE
At 30 June 2023 3,412,378
At 30 June 2022 3,203,167

Pharm - Tex Limited (Registered number: 02325397)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

5. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 30 June 2023 is represented by:

Shares in
group
undertakings
£
Valuation in 2023 209,211
Cost 3,203,167
3,412,378

The company owns 100% of the issued share capital of K Waterhouse Limited a company registered in the UK. The principal activity of K Waterhouse Limited is that of Wholesale Chemists.

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£ £
Amounts owed by group undertakings 177,991 196,741

7. RESERVES
Revaluation
reserve
£
At 1 July 2022 3,153,167
Investment in subsidiary 209,211

At 30 June 2023 3,362,378